Maurice was found pacing back and forth in front of his terminal, occasionally hurling banana peels at a whiteboard covered in quantum equations, muttering something about Schrödinger’s cat finally getting its lunch money.
Look, I’ve been thrown a lot of “revolutionary” investment opportunities in my time as Chief Banana Market Analyst. Most of them are about as revolutionary as yesterday’s banana peel. But then Foxy dropped this one on my desk—Schrödinger, Inc. (SDGR)—and I actually had to sit down for a moment. Not because I understood the quantum mechanics. I’m a monkey, not a physicist. But because I understood what was happening underneath the science: a company at the exact moment it pivots from selling expensive one-time licenses to selling the same intellectual property as a recurring revenue machine. That’s not just a business model change. That’s a financial transfiguration.
Here’s the thing about Schrödinger: it’s a physics-based computational platform for drug discovery. Translation for those of us who communicate primarily through banana-based metaphors: they built a software engine that simulates molecules at the quantum level, helping pharmaceutical companies discover new drugs faster than the old trial-and-error method. It’s the kind of deep-tech moonshot that makes venture capitalists throw money at problems. And for years, they were selling it the old way—perpetual licenses. Big upfront fees. Customers own it forever. The company gets paid once and watches the revenue dry up.
But something beautiful happened. They realized they could flip the script. Instead of “buy our software,” they’re moving to “rent our software as a service.” Hosted SaaS model. High margins. Recurring revenue. Predictability. It’s like discovering that instead of selling individual bananas at the market stand, you can offer a banana subscription service and make customers come back every single month. Except in this case, the bananas are actually helping cure cancer.
The numbers made me stop mid-peel. SDGR is sitting at $11.45 right now, with a market cap of just $845 million. Eight analysts covering it. A $22 price target. That’s 93% upside if they hit it. And here’s what made my tiny monkey eyes water: they posted $99.9 million in positive free cash flow. A software company with real, actual cash flowing in. Not a promise of cash. Not “we’ll be profitable in five years.” They already have it. Now they’re transitioning to a model that should be even more profitable.
The financial theater is genuinely compelling here. SDGR’s revenue growth looks a little wonky at -1.2% year-over-year, but that’s because they’re in the middle of the transition. They’re telling customers, “Hey, instead of buying a license, rent the hosted version.” Some of that old perpetual license revenue goes away. Some of the SaaS revenue hasn’t kicked in yet. It’s like watching someone mid-flip on a trapeze—for a split second, you’re wondering if they’re going to actually make the catch. But management publicly committed to EBITDA profitability in three years. Not “we hope to.” They said it. At a conference. With analysts listening. That’s either confidence or the most spectacular banana-slip in recent memory.
Now, I didn’t build my reputation throwing bananas randomly at price charts. Let me show you what worries me, because there’s real danger lurking here too.
First: that short ratio. 7.89%. That’s not just some casual shorting. That’s a significant number of folks betting against this thing. Why? Maybe because the transition is harder than management thinks. Maybe because the SaaS adoption takes longer than expected. Maybe because a competitor with deeper pockets (looking at you, major pharma) decides to build their own and give it away free. The short interest isn’t a reason to avoid SDGR, but it’s a weather report you should read before you leave the house.
Second: that debt-to-equity ratio. 30.026. I actually had to read that twice. That means SDGR is leveraged like a monkey swinging from a single vine over a canyon. For every dollar of equity, they’re carrying thirty dollars of debt. That’s not immediately catastrophic—especially if they’re generating real cash flow—but it means there’s no margin for error. If the SaaS transition stumbles, if customer acquisition slows, if that cash flow dries up, suddenly that debt becomes the scariest thing in the room.
Third: the stock’s been absolutely hammered. It’s trading at $11.45 after a 52-week high of $27.63. That’s a 59% collapse. Now, sometimes stocks collapse because they’re genuinely broken. Sometimes they collapse because the market got too excited, overcorrected, and created a genuine buying opportunity. The difference is whether the underlying business actually changed. In SDGR’s case, the business is actually improving. They’re making more cash. They’re transitioning to a better model. The stock drop seems to be more about investor disappointment with the perpetual license business and skepticism about the pivot. Which, frankly, is the classic setup for a re-rating if they execute.
Let me tell you what the bull case actually looks like, because it’s pretty compelling if you squint at it right.
Imagine SDGR nails the SaaS transition. In three years, they’re EBITDA profitable with 60-70% margins on that recurring revenue (typical for software). They’ve got a customer base of pharma companies, biotech firms, and materials science companies who need this simulation engine and have the budget to pay for it. Nobody else has this level of physics-based computational power wrapped into an easy-to-use platform. That’s a moat. Not an unbreachable one—but a real competitive advantage.
At that point, a software company generating meaningful cash with recurring revenue and predictable growth suddenly looks like it could trade at 15-20x EBITDA. We’re not talking theoretical valuation. We’re talking about what similar software companies actually trade for. Datadog. Cloudflare. ServiceTitan. These are 15-25x EBITDA trades for recurring, growing revenue. SDGR at 20x EBITDA on $50-60 million of EBITDA? You’re suddenly looking at a $1-1.2 billion valuation. That $22 price target starts looking conservative.
But here’s the problem: “if they execute.” That’s the banana peel everyone’s watching for.
The bear case is simpler and should scare you: the transition takes longer than expected. SaaS adoption requires different sales motions. The sales team isn’t equipped for it. Customers who bought perpetual licenses are price-sensitive as hell when it comes to SaaS subscriptions. Growth slows. That free cash flow evaporates because they’re burning cash trying to land SaaS customers. The debt becomes a problem. The stock goes to $7 instead of $22. And you’re holding a leveraged, late-stage clinical biotech platform company that’s slowly becoming obsolete.
This is why I’m giving SDGR a 7.5 on the Monkey Momentum Index. It’s not a 9 because the transition risk is real and the leverage is scary. It’s not a 6 because the business fundamentals are actually solid and the pivot makes strategic sense. It’s a 7.5 because it’s exactly what it claims to be: a medium-risk, long-term bet on a company at an inflection point.
If you’re the type of investor who can stomach watching this thing trade between $9 and $18 while the company executes over the next three years, this is genuinely interesting. If you need predictability and you’re going to panic sell at the first 30% dip, SDGR is going to be an absolute nightmare for you.
The entry point at $11.45 is reasonable. Not an absolute steal, but reasonable. The $22 target seems achievable if execution goes well. The $10.50 stop-loss gives you a 3% margin for error, which feels tight to me for a transition story, but I understand the logic.
I’m not saying buy SDGR with your rent money. I’m saying if you’ve got a three-year horizon, you believe in physics-based drug discovery, and you can handle the possibility that this thing trades down 40% before it trades up 93%, then this is exactly the kind of pre-inflection AI/biotech play that actually works out sometimes. Not always. Sometimes. But when it does, the people who bought at $11 look like geniuses.
Maurice is going to keep his eye on the Q1 SaaS adoption metrics. That’s the real tell. Not the revenue—the adoption. How many customers are switching to the hosted model? How fast are they signing up? That’s the number that determines whether this story has legs or whether the short-sellers have a point.
Disclaimer: Trained Market Money, Maurice, and our entire primate analysis team provide entertaining market commentary only. While Maurice’s Monkey Momentum Index™ and banana-based technical analysis have shown mysterious accuracy, they should never be considered financial advice. All investment decisions should be made in consultation with qualified financial professionals, not monkeys—no matter how impressive their fruit-throwing abilities may be. For real financial advice, please consult your financial advisor, who probably doesn’t accept bananas as payment.
Coming Next Week: We’re peeling back the layers on a semiconductor stock that looks cheaper than it has any right to be. Same time, same primate.
Maurice’s final wisdom: “Sometimes the quantum leap isn’t about the physics. It’s about whether the monkey throwing the bananas actually knows what he’s doing.”
Trained Market Monkey 